Allogeneic stem cell transplantation for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (sAML).
| Source . | Number of Patients . | Median Age (years) . | Outcome Calculated at N yrs. . | DFS or EFS (%) . | Relapse (%) . | TRM (%) . |
|---|---|---|---|---|---|---|
| # Transplantation for therapy-related MDS and AML (tMDS/tAML) | ||||||
| Notes: Nevill 1998: including 22 unrelated donors; Deeg 2002: age 46 yr overall; Anderson 1997: including 17 tAML and 29 sAML patients; Yakoub: including 8 unrelated donors, 3 mismatched related donors; Martino 2002: including 17 AML patients | ||||||
| Abbreviations: DFS, disease-free survival; EFS, event-free survival; TRM, treatment-related mortality | ||||||
| HLA-Identical Sibling | ||||||
| Anderson 1995 12 | 93 | 30 | 5 | 40 | 29 | 44 |
| Sutton 1996 3 | 71 | 37 | 7 | 32 | 48 | 39 |
| Runde 1998 14 | 131 | 33 | 5 | 34 | 39 | 44 |
| Nevill 1998 13 | 60 | 40 | 7 | 29 | 42 | 50 |
| De Witte 2000 6 | 885 | 33 | 3 | 36 | 36 | 43 |
| Sierra 2002 15 | 452 | 38 | 3 | 40 | 23 | 37 |
| Deeg 2002 7 | 41 | 46 | 3 | 56 | 16 | 28 |
| Anderson 1997 16 # | 46 | 42 | 5 | 24 | 31 | 44 |
| Yakoub-Agha 2000 18 # | 70 | 37 | 2 | 28 | 42 | 49 |
| Voluntary Unrelated Donor | ||||||
| Anderson 1996 27 | 52 | 33 | 2 | 38 | 28 | 48 |
| Arnold 1998 28 | 118 | 24 | 2 | 28 | 35 | 58 |
| De Witte 2000 6 | 198 | — | 3 | 25 | 41 | 58 |
| Deeg 2002 7 | 64 | 46 | 3 | 59 | 11 | 30 |
| Castro-Malaspina 2002 29 | 510 | 38 | 2 | 29 | 14 | 54 |
| Reduced Intensity Conditioning | ||||||
| Martino 2002 26 | 37 | 57 | 1 | 66 | 28 | 5 |
| Ho 2004 25 | 24 | 56 | 1 | 61 | 5 | |
| Ho 2004 25 (VUD) | 38 | 52 | 1 | 59 | 21 | |
| Source . | Number of Patients . | Median Age (years) . | Outcome Calculated at N yrs. . | DFS or EFS (%) . | Relapse (%) . | TRM (%) . |
|---|---|---|---|---|---|---|
| # Transplantation for therapy-related MDS and AML (tMDS/tAML) | ||||||
| Notes: Nevill 1998: including 22 unrelated donors; Deeg 2002: age 46 yr overall; Anderson 1997: including 17 tAML and 29 sAML patients; Yakoub: including 8 unrelated donors, 3 mismatched related donors; Martino 2002: including 17 AML patients | ||||||
| Abbreviations: DFS, disease-free survival; EFS, event-free survival; TRM, treatment-related mortality | ||||||
| HLA-Identical Sibling | ||||||
| Anderson 1995 12 | 93 | 30 | 5 | 40 | 29 | 44 |
| Sutton 1996 3 | 71 | 37 | 7 | 32 | 48 | 39 |
| Runde 1998 14 | 131 | 33 | 5 | 34 | 39 | 44 |
| Nevill 1998 13 | 60 | 40 | 7 | 29 | 42 | 50 |
| De Witte 2000 6 | 885 | 33 | 3 | 36 | 36 | 43 |
| Sierra 2002 15 | 452 | 38 | 3 | 40 | 23 | 37 |
| Deeg 2002 7 | 41 | 46 | 3 | 56 | 16 | 28 |
| Anderson 1997 16 # | 46 | 42 | 5 | 24 | 31 | 44 |
| Yakoub-Agha 2000 18 # | 70 | 37 | 2 | 28 | 42 | 49 |
| Voluntary Unrelated Donor | ||||||
| Anderson 1996 27 | 52 | 33 | 2 | 38 | 28 | 48 |
| Arnold 1998 28 | 118 | 24 | 2 | 28 | 35 | 58 |
| De Witte 2000 6 | 198 | — | 3 | 25 | 41 | 58 |
| Deeg 2002 7 | 64 | 46 | 3 | 59 | 11 | 30 |
| Castro-Malaspina 2002 29 | 510 | 38 | 2 | 29 | 14 | 54 |
| Reduced Intensity Conditioning | ||||||
| Martino 2002 26 | 37 | 57 | 1 | 66 | 28 | 5 |
| Ho 2004 25 | 24 | 56 | 1 | 61 | 5 | |
| Ho 2004 25 (VUD) | 38 | 52 | 1 | 59 | 21 | |